|Home | About | Donate/Volunteer | Contact | Jobs| Early Schizophrenia Screening Test||
August 02, 2005
Atypicals Curb Loss of Brain Cells
Read more... Schizophrenia Medications
A new study has come out suggesting that the antipsychotic drug olanzapine keeps those with schizophrenia from losing grey matter from the brain; the older drug haloperidol apparently does not have the same benefits. We believe that this study was likely funded by the Eli Lilly, the makers of Olanzapine (Zyprexa) - so, as with any information published by a company, you have to be skeptical of the results and potential bias that tends to be common in these types of trials.
The research was published in the Archives of General Psychiatry. Increasingly, research is showing that the atypical antipsychotic medications seem to share this ability to slow the grey matter loss that is characteristic of schizophrenia.
If the findings are confirmed by other studies than this would imply that the newer atypical antipsychotics are preferable. This would supposedly keep the illness from progressing if medication was started earlier. Previous research looking at brain matter loss in adolescents with schizophrenia has indicated that early intervention could prevent the damage.
The brain's gray matter holds most of a human beings brain cells, as well as the "billions of connections among the cells." Losing gray matter has been associated with social withdrawal as well as other perceived negative symptoms of schizophrenia. This story also reminds readers that the fact that schizophrenia can cause brain deterioration has only been known by scientists for the last 10 years.
The source of this article is The Detroit News. Written there by Robert Preidt.
You can find the full article at http://tinyurl.com/ckbov.
The research article is by Lieberman JA. "Recent advances in the clinical use of atypical antipsychotics". CNS Spectr. 2005 Aug;10(8 Suppl 8):4.
Posted by christine at August 2, 2005 02:10 PM
More Information on Schizophrenia Medications